X-Linked Hypophosphatemia Market Share, Potential Growth, Demand And Analysis Of Key Players- Research Forecasts To 2028


Market Highlights

The Global X-linked Hypophosphatemia Market is estimated to be valued at USD 40,309.1 Thousand by 2025 and is expected to register a CAGR of 3.6% during the forecast period.

X-linked hypophosphatemia (XLH) is a rare genetic disorder caused by mutations in the phosphate regulating endopeptidase homolog (PHEX), X-Linked gene. XLH is also called as X-linked hypophosphatemic rickets, vitamin D-resistant rickets (VDRR), familial hypophosphatemic rickets, or genetic rickets.

The global X-linked hypophosphatemia market is mainly driven by factors such as rising cases of X-linked hypophosphatemia, increasing awareness about XLH and the severity of the disease, and the proactive initiatives for researching the field of XLH. However, the high cost of the drug and limited availability of treatment options may slow down the growth of the market in the future. On the other hand, a recent drug approval by regulatory authorities such as the US FDA, Health Canada, and the European Medical Agency is likely to offer lucrative opportunities for the growth of the market shortly.

Get Sample Report: https://www.marketresearchfuture.com/sample_request/6267

Segment Analysis

The X-linked hypophosphatemia (XLH) market by treatment has been segmented into medication and surgical or orthopedic treatment. According to a press release by the US FDA in April 2018, XLH affected approximately 3,000 children and 12,000 adults in the US alone. The increasing number of people suffering from phosphate deficiency is driving the X-Linked Hypophosphatemia market as this raises the demand for the treatment of this disease.

The X-linked hypophosphatemia market has been categorized by the end user into hospitals and clinics and research centers. The hospitals and clinics segment is expected to register a relatively good CAGR during the forecast period from 2019 to 2025. A regular rise in the number of private and government hospitals in developing countries such as India, China, and Indonesia with an increase in the number of diagnosis and treatment procedures for X-linked disorders is expected to support the profitable growth of this segment. According to the survey conducted by the American Hospital Association (AHA), the total number of hospitals in the US are 6,210. Also, the increase in the use of medication, corrective surgery, and dental procedure to cure XLH is supporting the growth of this segment.

Regional Analysis

The XLH market in the Americas is expected to hold a major market share owing to the growing prevalence of XLH in the US and Canada and the presence of a well-established healthcare sector. The rising research funding towards rare diseases such as XLH and the high healthcare expenditure is also expected to fuel the growth of the market during the forecast period. For instance, Genome Canada and the Canadian Institutes for Health Research entered into a partnership to study rare genetic diseases by using Next-Generation Sequencing (NGS) technology.

Followed by America, the European market is expected to be the second-largest X-linked hypophosphatemia market. The rising prevalence rates of XLH, technological advances, well-developed health care sector, and government support for the research and development have fueled the growth of the market.

Asia-Pacific is anticipated to be the fastest-growing market owing to the growing healthcare expenditure and the presence of a large patient pool. Growing investments by market players in the region due to the growing demand for the treatment of rare diseases is expected to contribute to the growth of the market.

Browse Full Report Details @ https://www.marketresearchfuture.com/reports/x-linked-hypophosphatemia-market-6267

Market Players

Market Research Future (MRFR) recognizes Ultragenyx Pharmaceutical (California), Validus Pharmaceuticals LLC (New Jersey), Prospec-Tany Technogene Ltd (Israel), Merck KGaA (Germany), Zeria Pharmaceutical Co., Ltd (Japan), Smith & Nephew (UK), Narang Medical Limited (India), Eli Lilly and Company (Indiana). F. Hoffmann-La Roche (Switzerland) as the key players in the global X-linked hypophosphatemia market.

Key Findings of the Study:

The Global X-linked Hypophosphatemia Market is projected to reach over USD 40,309 thousand by 2025 at a 6% CAGR during the review period of 2019 to 2025.

Asia-Pacific accounted for the largest market share, with Japan being the major contributor to the growth of the market.

The treatment segment is projected to register the highest CAGR of 3.6% during the forecast period as according to the statistics published in 2017 by the Food and Drug Administration (FDA), XLH affected an approximate of 3,000 children and 12,000 adults in the US.

Key manufacturers are adopting geographic expansions, corporate acquisitions, and product launches as growth strategies. Moreover, they are focusing on e-commerce for distribution.

 About US:

Market Research Future (MRFR) enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street,5Th Floor, New York,

New York 10013

 

Comments

Post a Comment

Popular posts from this blog

Ayurvedic Products Market Outlook, Trend, Growth and Share Estimation Analysis and Forecast 2020-2030

Image
  Global Ayurvedic Products Market Overview Ayurvedic Products are generally used in personal care and healthcare products. Ayurvedic products originated from India, and thus, the concentration of ayurvedic product suppliers is the highest in the country. According to the latest research reports Due to growing inclination for natural treatment, the Ayurvedic Products Market , size is projected to reach USD 28830.5 Million by 2030 at 12.3% CAGR. Many factors are influencing a significant rise in the growth rate between during forecast periods. Increasing adoption of traditional methods for medicinal purposes is observed to cause a significant boost in the global Ayurvedic Products Market With a rise in the working woman population, rising disposable income, and a growing inclination towards chemical free and herbal cosmetics are some of the primary factors contributing to the ascension of the global ayurvedic market. Apart from personal care, ayurvedic healthcare products are...
Read more

Pain Management Devices Market Set To Exhibit Strong Growth, Valuable Research Factors and Industry Forecast to 2030

Image
  Pain Management Devices Market – Overview The Pain Management Devices Market can anticipate expansion at a rate of 7.12% from 2020 to 2030, believes MRFR (Market Research Future). Progress in technology and better research capabilities have led to the development of devices that can control pain with limited use of drugs. Focused Market reports connected to the healthcare sector among others lately have been made available by Market Research Future which publishes a report on this sector. The development of pain management devices has been useful to control pain in a wide range of ailments. The level of relief from pain that is experienced, is one of the major driving factors for the industry, as patients who use such devices are prone to chronic pain daily. Cancer patients and the geriatric population are among the major user segments for the pain management devices as medication alone may not be sufficient to provide pain relief in their situation. The industry is antici...
Read more

Breast Cancer Market 2022-2027 Worldwide Demand and Growth Analysis Report 2022-2027

Image
  Breast Cancer is the second-most common type of cancer in women and one of the paramount concerns, globally. According to WHO, every year, around 200,000 new cases get registered, and the digits are continuously increasing. Many statistics show that breast cancer is more prevalent in developed countries such as the UK, the US, and Australia as their women are more prone to acquire the disease. This doesn’t mean that women from developing countries like India and China are out of breast cancer’s radar. On the contrary, they are more vulnerable than women from developed regions. Unavailability of proper treatment due to the lack of funds and awareness towards the government’s programs is killing them more than breast cancer can. Advancements in medical science and biotechnology have improved the outlook of diagnosis. However, the recovery is still challenging as survivors adjust to the scars that remain mentally and physically. Surprisingly, the Breast Cancer Market is still a...
Read more